AXLA

In a report released today, Keay Nakae from Chardan Capital reiterated a Buy rating on Axcella Health (AXLA - Research Report), with a price target of $7.00. The company's shares closed last Friday at $2.33.Nakae covers the Healthcare sector, focusing on stocks such as Better Therapeutics, Inc., Arbutus Biopharma, and ProQR. According to TipRanks, Nakae has an average return of 7.8% and a 41.76% success rate on recommended stocks. Currently, the analyst consensus on Axcella Health is a Strong Buy with an average price target of $8.25, which is a 254.08% upside from current levels.
https://www.tipranks.com/news/blurbs/axcella-health-axla-gets-a-buy-from-chardan-capital?utm_source=advfn.com&utm_medium=referral